The Pennant Group, Inc.

The Pennant Group, Inc. (PNTG) Market Cap

The Pennant Group, Inc. has a market capitalization of $1.05B.

Financials based on reported quarter end 2025-12-31

Price: $30.11

0.74 (2.52%)

Market Cap: 1.05B

NASDAQ · time unavailable

CEO: Brent J. Guerisoli

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2019-10-01

Website: https://www.pennantgroup.com

The Pennant Group, Inc. (PNTG) - Company Information

Market Cap: 1.05B · Sector: Healthcare

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors, who are independent or who require some support. As of December 31, 2021, the company operated 88 home health and hospice agencies, and 54 senior living communities with 4127 Senior Living units in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

Analyst Sentiment

79%
Strong Buy

Based on 7 ratings

Analyst 1Y Forecast: $39.00

Average target (based on 3 sources)

Consensus Price Target

Low

$38

Median

$39

High

$40

Average

$39

Potential Upside: 29.5%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PENNANT GROUP INC (PNTG) — Investment Overview

🧩 Business Model Overview

The Pennant Group, Inc. (PNTG) operates as a leading provider of healthcare services, specializing in home health, hospice, and senior living solutions. Structured as a pure-play post-acute care provider, Pennant operates a decentralized business model, granting significant autonomy to local field leaders at its portfolio of operations. Such a structure enables enhanced responsiveness to market dynamics, fosters entrepreneurial cultures, and allows for tailored offerings in the communities the company serves. Pennant’s strategy centers around disciplined acquisitions, organic growth, and operational efficiency, predominantly targeting underserved or fragmented geographic markets throughout the United States.

💰 Revenue Streams & Monetisation Model

Pennant Group generates its revenue through three primary operating segments: 1. **Home Health Services:** Pennant delivers skilled nursing, therapy, and other health services directly to patients in their homes, typically under Medicare reimbursement, commercial insurance, and certain government programs. 2. **Hospice Services:** Under its hospice segment, the company provides end-of-life care, focusing on both the comfort of patients and support for families. Reimbursements are generally from Medicare, which covers most hospice patients, with additional revenue from Medicaid and private payers. 3. **Senior Living Services:** Pennant owns and operates assisted living, independent living, and memory care communities. Revenues in this segment are generated primarily on a private-pay basis, including monthly resident fees that cover housing, meals, and personal care. Pennant’s business model emphasizes cost-effective, high-quality care, balancing occupancy rates and labor controls, and leveraging technology for operational efficiencies.

🧠 Competitive Advantages & Market Positioning

Pennant’s most distinctive competitive advantage lies in its decentralized operating model, empowering local leaders to respond rapidly to market needs and compete more effectively at a local level. This entrepreneurial structure is a significant differentiator relative to more centralized, bureaucratic peers and fosters a culture of accountability and performance. Scale provides Pennant with operational leverage and purchasing power, yet its asset-light approach within home health and hospice limits capital intensity compared to traditional skilled nursing or hospital operators. The company targets demographically favorable markets with growth potential, favoring suburban and secondary metro regions that may be underserved by larger chains. Its disciplined acquisition strategy has established a robust pipeline for tuck-in opportunities, often acquiring underperforming operations and integrating them into its operational playbook. The diversified mix across home health, hospice, and senior living offers some resilience to regulatory change or reimbursement rate pressures within a single service line.

🚀 Multi-Year Growth Drivers

Several secular and company-specific catalysts support Pennant’s long-term growth trajectory: - **Aging Population:** The aging U.S. demographic—particularly the 65+ cohort—is expanding, increasing demand for home health, hospice, and senior living solutions. - **Preference for Home-based Care:** Healthcare payers and regulators increasingly incentivize lower-cost, home-based care, a setting preferred by patients and families, fueling volume growth and reimbursement opportunities. - **Acquisition Pipeline:** The post-acute market remains fragmented, with numerous small operators lacking scale or succession plans. Pennant’s M&A expertise and disciplined integration provide a persistent source of growth via geographic expansion and market share gains. - **Operational Improvements:** The company focuses on operational efficiencies, driving organic growth through enhanced census, higher occupancy, and margin expansion. - **Favorable Regulatory Environment:** Although healthcare regulation is always evolving, broad policy support for hospice and home health reimbursement—including value-based care pilots—creates pathways for innovation and volume growth. - **Care Model Innovation:** Investments in technology, patient engagement, and care coordination may unlock further efficiencies and positioning as value-based payment models become more prevalent.

⚠ Risk Factors to Monitor

Pennant's investment case is not without risk. Key areas to monitor include: - **Reimbursement Pressure:** The business is highly sensitive to Medicare and Medicaid reimbursement rates, which are subject to federal and state budgetary cycles and policy changes. - **Labor Market Constraints:** The healthcare services industry faces acute labor challenges, particularly recruiting and retaining skilled nurses, therapists, and caregivers. Wage inflation or staffing shortages may pressure margins or impede growth. - **Integration Risk:** The company’s reliance on tuck-in acquisitions introduces potential operational integration, dilution, or cultural assimilation risks. - **Regulatory and Compliance Risk:** An evolving regulatory landscape exposes Pennant to risks regarding licensing, billing practices, and care quality standards. Non-compliance could result in penalties or exclusion from payer programs. - **Competition:** Larger, well-capitalized competitors or regional specialists may challenge Pennant in core service lines, potentially impacting pricing or cost structure. - **Occupancy/Census Volatility:** Particularly in senior living, occupancy rates can fluctuate with macroeconomic, competitive, or infectious disease trends.

📊 Valuation & Market View

Pennant is typically valued on a mix of revenue multiples and adjusted EBITDA, reflecting its capital-light model and growth profile. Investment community sentiment is frequently influenced by the company’s demonstrated ability to drive organic revenue growth, execute accretive acquisitions, and expand margins despite labor and regulatory headwinds. The company often trades at a premium to traditional facility-based peers due to its focus on the faster-growing home health and hospice segments. Conversely, valuation is tempered by the sector’s sensitivity to policy shifts and operational execution. Market consensus generally factors in Pennant’s strong pipeline of acquisition opportunities and the secular tailwinds of an aging population, while monitoring wage pressure and reimbursement risk. Investors place value on management’s M&A track record and decentralized approach, provided the company continues to balance growth with financial discipline.

🔍 Investment Takeaway

The Pennant Group presents a compelling investment proposition for investors seeking exposure to secular trends in post-acute and senior care. Its multi-pronged strategy—combining disciplined acquisitions, organic growth, and a unique decentralized operating model—positions the company to capture substantial long-term market share in a fragmented healthcare services landscape. The company’s diversification across home health, hospice, and senior living partially insulates it against volatility in any single vertical. Meaningful growth catalysts, including demographic shifts and accelerating preferences for home-based care, remain firmly in place. However, ongoing vigilance is warranted regarding reimbursement frameworks, labor market trends, and integration execution. While not immune to sector headwinds, Pennant’s focus on operational excellence and M&A-driven expansion offer sustained opportunities for value creation, meriting its consideration as a core holding within a healthcare-focused portfolio.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"PNTG reported revenue of $289.32M and a net income of $8.64M for the fiscal year ending December 31, 2025. Earnings per share stood at $0.25, reflecting moderate profitability in a growing business. The company generated operating cash flow of $20.96M and maintained a free cash flow of $13.97M, showing solid cash generation relative to its earnings. With total assets of $968.18M and total liabilities of $593.93M, PNTG maintains a strong balance sheet, resulting in total equity of $374.25M. The net debt stands at $436.14M, indicating a leveraged position that investors should monitor. Over the past year, PNTG's share price has appreciated by 27.71%, illustrating strong market performance, without any dividends paid. This indicates a focus on growth, potentially reinvesting earnings rather than returning capital to shareholders. The stock's current price of $31.02 suggests room for further appreciation towards the median price target of $39, aligning with optimistic analyst sentiment."

Revenue Growth

Good

Strong revenue generation of $289.32M indicates positive growth.

Profitability

Neutral

Net income of $8.64M shows moderate profitability but room for improvement.

Cash Flow Quality

Good

Positive free cash flow of $13.97M reflects good cash management.

Leverage & Balance Sheet

Positive

Managed leverage with net debt of $436.14M against strong assets.

Shareholder Returns

Good

Exceptional price appreciation of 27.71% over last year with no dividends.

Analyst Sentiment & Valuation

Good

Consensus price target suggests significant upside potential from current levels.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered a strong Q4 and 2025 finish but signaled that 2026 will be constrained by near-term execution. Reported momentum is real: home health admissions +81.3% and Medicare admissions +87.5% YoY, with CMS stars rising to 4.2; hospice quality composite is 97.5% with daily census up 46.9% to 5,060. Senior living also improved materially, with occupancy +200 bps to 80.6% (same-store +250 bps to 82.1%). However, the core “So what?” is the guidance posture. Analysts pressed that 2026 looks conservative, and management explicitly attributed it to integration “noise” across the first 3 quarters—system and branding transitions plus added national support—along with home health rule pressure (modeled 1.3% rate decrease). They still underwrote same-store home health/hospice revenue growth of +7% and expect only “a few basis points” margin expansion despite reimbursement softness. Net: strong operational wins, but analyst scrutiny centers on whether integration and reimbursement timing can be normalized fast enough.

AI IconGrowth Catalysts

  • Home health admissions surge: Q4 admissions +81.3% and Medicare admissions +87.5% YoY
  • Organic same-store momentum in home health: same-store Medicare admissions +8.2% and Medicare revenue per episode +3.7% YoY
  • CMS quality strength: home health average CMS star rating rose to 4.2 (vs national avg 3.0)
  • Hospice census and quality flywheel: Q4 hospice Medicare quality composite score 97.5% driving all-time high average daily census 5,060 (+46.9% YoY)
  • Senior living operational improvement: Q4 occupancy +200 bps to 80.6% and same-store occupancy +250 bps to 82.1%

Business Development

  • Acquisition completed Jan 1, 2025: Signature Healthcare at Home (Pacific Northwest) integrated into Pennant model
  • October 2025: purchase of 50+ locations from UnitedHealth and Amedisys (Southeast expansion / Tennessee integration focus)
  • Joint venture strategy referenced: University of Tennessee JV (Northeastern Tennessee); approach includes collaborating with acute health system partners
  • Q4 senior living acquisitions: Nov 1 acquisition of Twin Rivers Senior Living (55 beds, Lewiston, Idaho); Nov 4 acquisition of Honey Creek Heights Senior Living real estate (adds 135 assisted living beds to Midwest; West Dallas, Wisconsin)

AI IconFinancial Highlights

  • Q4 adjusted EPS: $0.34
  • Full-year 2025 adjusted EPS: $1.18, exceeding updated guidance midpoint of $1.16
  • Full-year 2025 revenue: $947.7M (+$252.5M / +36.3% YoY)
  • Full-year 2025 adjusted EBITDA: $72.5M (+$19.2M / +36% YoY)
  • Full-year 2025 adjusted EBITDA prior to NCI: $76.7M (+$21.6M / +39.2% YoY)
  • 2026 guidance (full-year, annual): Revenue $1.13B–$1.17B (midpoint +22.4%); adjusted EBITDA $88.5M–$94.1M (midpoint +26%); adjusted EBITDA prior to NCI $94.2M–$100.0M (midpoint +26.7%); adjusted EPS $1.26–$1.36 (midpoint $1.31)
  • Guidance conservatism explicitly attributed to integration 'noise' from transitioning UnitedHealth/Amedisys operations and systems plus name/branding changes across the first 3 quarters of 2026
  • Effective tax rate embedded in 2026 guidance: 26%
  • Home health rule / reimbursement pressure: modeled softness with a '1.3% rate decrease' expectation in the segment; management expects initiatives to still drive margin expansion 'a few basis points' in 2026

AI IconCapital Funding

  • Credit facility expanded: added $100M term loan; total facility $350M
  • UnitedHealth acquisition investment: $147.2M (October)
  • Leverage: net debt / adjusted EBITDA 1.7x (covenant limit 3.25x)
  • Cash flow: Q4 cash from operations $21M; year-to-date $48.3M
  • Cash on hand at year-end: $17M
  • 2026 liquidity plan: fund future growth and pay down outstanding debt during the year via robust earnings and collections

AI IconStrategy & Ops

  • Integration timeline: transition and integration of former Amedisys and UnitedHealth operations in waves; expected completion of all waves by October 2026
  • Management expects initial 'choppiness' in early results due to system/branding transition; guidance anticipates this
  • Home health/hospice guidance build: same-store home health and hospice revenue modeled +7% for 2026
  • Senior living modeling assumptions: occupancy increase ~100 bps over the year; RevPOR increases ~6% (mirroring 2025 rate/RevPOR trend)
  • G&A planning assumption: G&A modeled at 6.4%–6.5% of revenue for 2026

AI IconMarket Outlook

  • 2026 is explicitly framed as a transition year with ramp throughout the year (particularly first-half) and optimization by end of year into 2027
  • Management states same-store earnings/margin approach for home health/hospice: despite home health rule pressure and expected 1.3% rate decrease, initiatives should enable margin expansion 'a few basis points' in 2026

AI IconRisks & Headwinds

  • Integration execution risk: UnitedHealth/Amedisys transition includes operating system changes and name/branding transitions across first 3 quarters of 2026; requires additional national support during transition
  • Reimbursement headwinds: guidance incorporates 'home health rule' impacts causing revenue softness; modeled 1.3% rate decrease
  • Transition services agreement and deal-specific support complexity: explicitly called out as a unique element of the United/Amedisys deal (risk to near-term normalization)

Sentiment: MIXED

Note: This summary was synthesized by AI from the PNTG Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PNTG)

© 2026 Stock Market Info — The Pennant Group, Inc. (PNTG) Financial Profile